Holmes RS, et al. - Via searching MEDLINE and two Cochrane databases through February 2018, researchers assessed evidence comparing the benefits and harms of long-acting insulin treatments in patients with type 1 and 2 diabetes in this systematic review and meta-analysis. For this investigation, they included comparative studies of adult or pediatric patients with diabetes treated with insulin degludec, detemir, or glargine. According to findings, there were no differences in glycemic control between insulin degludec, detemir, and glargine. Degludec was less likely to cause hypoglycemia than glargine. Detemir-treated adults gained approximately 1 kg less body weight than degludec (type 1) or glargine (type 2). In patients with type 2 diabetes, withdrawals were more likely with detemir than with glargine because of adverse events. Between any two insulins or formulations, they did not observe any statistically significant differences in hemoglobin A1c.